2012 ASCO Annual Meeting Slide show

Chicago, IL - ASCO 2012 Annual Meeting: - Mary-Ellen Taplin, MD Effect of neoadjuvant abiraterone acetate (AA) plus leuprolide acetate (LHRHa) on PSA, pathological complete response (pCR), and near pCR in localized high-risk prostate cancer (LHRPC): Results of a randomized phase II study. during Neoadjuvant androgen pathway suppression prior to prostatectomy. at the American Society for Clinical Oncology (ASCO) Annual Meeting here today, Saturday June 2, 2012. Over 25,000 physicians, researchers and healthcare professionals from over 100 countries are attending the meeting which is being held at the McCormick Convention center and features the latest cancer research in the areas of basic and clinical science. Photo by © ASCO/Silas Crews 2012 Technical Questions: todd@toddbuchanan.com; ASCO Contact: photos@asco.org

MaryEllen TaplinMD Neoadjuvant androgen pathway suppression prior to prostatectomy. Effect of neoadjuvant abiraterone acetate AA plus leuprolide acetate LHRHa on PSApathological complete response pCRand near pCR in localized highrisk prostate cancer LHRPC Results of a randomized phase II study.12asco00352